Long-term population-based outcomes of adjuvant trastuzumab in HER2-positive early breast cancer: The British Columbia experience.

Trial Profile

Long-term population-based outcomes of adjuvant trastuzumab in HER2-positive early breast cancer: The British Columbia experience.

Completed
Phase of Trial: Phase IV

Latest Information Update: 30 May 2014

At a glance

  • Drugs Trastuzumab (Primary)
  • Indications Breast cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 30 May 2014 Results presented at the 50th Annual Meeting of the American Society of Clinical Oncology.
    • 26 May 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top